Skip to main content
. 2015 Sep 18;7(20):2245–2263. doi: 10.4254/wjh.v7.i20.2245

Figure 1.

Figure 1

An illustrative case showing discrepancies between subsequent criteria used to assess tumor response in a patient treated with sorafenib for hepatocellular carcinoma. HCC: Hepatocellular carcinoma; CT: Computed tomography; RECIST: Response evaluation criteria in solid tumors; mRECIST: Modified RECIST.